Precision BioSciences
Develops ARCUS-based in vivo gene-editing therapies.
$7.85
After-hours close+0.07 (+0.90%)
At close$7.78(−7.38%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 125.90%Insiders 6.30%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 12.83M · Float 9.85M · 76.8% free float
Institutions13F, as of Mar 31, 2026
78 holders · 16.15M shares · 21 new positions · 45 increased · 13 reduced · 11 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 2.24M | 17.44% | +318.7K | May 15, 2026 |
| Abrdn PLC | 2.23M | 17.39% | +91.6K | Apr 29, 2026 |
| Empery Asset Management, LP | 1.97M | 15.35% | −225.8K | May 8, 2026 |
| Bleichroeder LP | 1.66M | 12.96% | 0 | May 14, 2026 |
| Boothbay Fund Management, LLC | 1.07M | 8.31% | 0 | May 15, 2026 |
| Driehaus Capital Management LLC | 995.4K | 7.76% | +207.7K | May 15, 2026 |
| LYNX1 Capital Management LP | 985.1K | 7.68% | −8.8K | May 4, 2026 |
| Vanguard Capital Management LLC | 910.7K | 7.10% | +910.7Knew | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Octagon Capital Advisors LP | 9.99% | 2.33M | 13G | Feb 10, 2026 ↗ |
| Readout Capital, LP | 9.30% | 1.11M | 13G | Aug 14, 2025 ↗ |
| Aberdeen Group plc | 8.88% | 2.14M | 13G | Jan 27, 2026 ↗ |
| Bleichroeder LP | 8.21% | 1.90M | 13G | Feb 13, 2026 ↗ |
| Empery Asset Management, LP | 7.63% | 1.97M | 13G | Apr 15, 2026 ↗ |
| Lynx1 Capital Management LP | 5.40% | 1.39M | 13G | Jul 20, 2026 ↗ |
| Highbridge Capital Management, LLC | 5.30% | 406.3K | 13G | Nov 14, 2024 ↗ |
| Weinstein Benjamin | 5.20% | 395.5K | 13G | Mar 18, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Michael Amoroso | director, officer: President and CEO | 243.4K | 1.90% | Feb 19, 2026 |
| John Alexander Kelly | officer: Chief Financial Officer | 125.9K | 0.98% | Feb 19, 2026 |
| J. Jefferson Smith | officer: Chief Research Officer | 121.9K | 0.95% | Feb 19, 2026 |
| Dario Scimeca | officer: General Counsel and Secretary | 56.5K | 0.44% | Feb 19, 2026 |
| Kevin Buehler | director | 49.1K | 0.38% | May 22, 2026 |
| Geno J. Germano | director | 44.9K | 0.35% | May 22, 2026 |
| Melinda Brown | director | 44.3K | 0.35% | May 22, 2026 |
| Stanley Frankel | director | 40.5K | 0.32% | May 22, 2026 |
| Shari Lisa Pire | director | 35.0K | 0.27% | May 22, 2026 |
| Naresh Haresh Tanna | officer: Chief Financial Officer | 25.6K | 0.20% | Aug 3, 2026 |
2 ten-percent owners hold 522.9K shares by Form 4, outside the officers-and-directors figure above · 11 people have not refiled in the last 18 months (228.6K shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Feb 18, 2026 | J. Jefferson Smithofficer: Chief Research Officer | Sale | 4,925 | $3.84 | 121,926 |
| Feb 18, 2026 | Dario Scimecaofficer: General Counsel and Secretary | Sale | 4,925 | $3.84 | 56,457 |
| Feb 18, 2026 | John Alexander Kellyofficer: Chief Financial Officer | Sale | 8,149 | $3.84 | 125,883 |
| Feb 18, 2026 | Michael Amorosodirector, officer: President and CEO | Sale | 20,559 | $3.84 | 243,392 |
| Jan 21, 2026 | J. Jefferson Smithofficer: Chief Research Officer | Sale | 10,200 | $4.03 | 110,184 |
| Jan 21, 2026 | John Alexander Kellyofficer: Chief Financial Officer | Sale | 15,213 | $4.03 | 106,448 |
| Jan 21, 2026 | Dario Scimecaofficer: General Counsel and Secretary | Sale | 8,854 | $4.03 | 44,715 |
| Jan 22, 2026 | Michael Amorosodirector, officer: President and CEO | Sale | 34,799 | $4.17 | 196,154 |
| Dec 15, 2025 | Melinda Browndirector | Purchase | 1,381 | $4.97 | 23,346 |
| Dec 16, 2025 | Stanley Frankeldirector | Purchase | 2,700 | $4.70 | 19,478 |
CongressHouse and Senate disclosures
Not reported.